PRME Stock Analysis: Buy, Sell, or Hold?
PRME - Prime Medicine, Inc. Common Stock
$3.39
0.15 (4.63%)
▲
5d:
+9.71%
30d:
+14.14%
90d:
+14.92%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When PRME Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PRME shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PRME shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: PRME is currently trading at $3.39, which is considered extended relative to its 30-day fair value range of $2.96 to $3.32.
Technical Outlook: Technically, PRME is in a strong uptrend. Immediate support is located at $3.00, while resistance sits at $3.59. The stock is showing strong short-term momentum, up 4.6% recently.
Market Sentiment: PRME scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.12 (+110.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PRME is in a strong uptrend. Immediate support is located at $3.00, while resistance sits at $3.59. The stock is showing strong short-term momentum, up 4.6% recently.
Market Sentiment: PRME scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.12 (+110.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.96 -
$3.32
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
31.6%
Protect Your Profits
Holding PRME? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.6%)
- BULLISH: Trading 110.2% below Wall St target ($7.12)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.96 -
$3.32
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.00
Resistance Level
$3.59
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.92
Wall Street Target
$7.13
(+110.2%)
Revenue Growth (YoY)
3.5%
Share & Embed Analysis
Last updated: August 23, 2026 5:51 PM ET
Data refreshes hourly during market hours. Next update: 6:51 PM
Data refreshes hourly during market hours. Next update: 6:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRME showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
Advanced PRME Option Strategies
Professional options setups generated by AI based on today's PRME price and gamma walls.
